Table of Content

1 Postmenopausal Vaginal Atrophy Drugs Market Overview
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Postmenopausal Vaginal Atrophy Drugs Segment by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Vaginal Gels
1.2.3 Creams
1.2.4 Tablets
1.2.5 Rings
1.2.6 Patches
1.3 Postmenopausal Vaginal Atrophy Drugs Segment by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Offline Stores
1.3.3 Online Stores
1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2016-2027
1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2027
1.4.3 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Postmenopausal Vaginal Atrophy Drugs Market Competition by Manufacturers
2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites, Area Served, Product Type
2.5 Postmenopausal Vaginal Atrophy Drugs Market Competitive Situation and Trends
2.5.1 Postmenopausal Vaginal Atrophy Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue
2.5.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario by Region
3.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.3.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.4.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.4.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
3.5.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.6.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.6.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
3.7.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Analysis by Type
4.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2021)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2016-2021)

5 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Analysis by Application
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2021)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Actavis plc
6.1.1 Actavis plc Corporation Information
6.1.2 Actavis plc Description and Business Overview
6.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.1.5 Actavis plc Recent Developments/Updates
6.2 Bionovo, Inc.
6.2.1 Bionovo, Inc. Corporation Information
6.2.2 Bionovo, Inc. Description and Business Overview
6.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.2.5 Bionovo, Inc. Recent Developments/Updates
6.3 Endoceutics, Inc.
6.3.1 Endoceutics, Inc. Corporation Information
6.3.2 Endoceutics, Inc. Description and Business Overview
6.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.3.5 Endoceutics, Inc. Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 Teva Pharmaceuticals Ltd.
6.6.1 Teva Pharmaceuticals Ltd. Corporation Information
6.6.2 Teva Pharmaceuticals Ltd. Description and Business Overview
6.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.6.5 Teva Pharmaceuticals Ltd. Recent Developments/Updates
6.7 Therapeutics MD, Inc.
6.6.1 Therapeutics MD, Inc. Corporation Information
6.6.2 Therapeutics MD, Inc. Description and Business Overview
6.6.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.7.5 Therapeutics MD, Inc. Recent Developments/Updates
6.8 Shionogi & Company
6.8.1 Shionogi & Company Corporation Information
6.8.2 Shionogi & Company Description and Business Overview
6.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.8.5 Shionogi & Company Recent Developments/Updates
6.9 Allergan plc
6.9.1 Allergan plc Corporation Information
6.9.2 Allergan plc Description and Business Overview
6.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.9.5 Allergan plc Recent Developments/Updates
6.10 Shionogi & Co. Ltd.
6.10.1 Shionogi & Co. Ltd. Corporation Information
6.10.2 Shionogi & Co. Ltd. Description and Business Overview
6.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Portfolio
6.10.5 Shionogi & Co. Ltd. Recent Developments/Updates

7 Postmenopausal Vaginal Atrophy Drugs Manufacturing Cost Analysis
7.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
7.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Postmenopausal Vaginal Atrophy Drugs Distributors List
8.3 Postmenopausal Vaginal Atrophy Drugs Customers

9 Postmenopausal Vaginal Atrophy Drugs Market Dynamics
9.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
9.2 Postmenopausal Vaginal Atrophy Drugs Growth Drivers
9.3 Postmenopausal Vaginal Atrophy Drugs Market Challenges
9.4 Postmenopausal Vaginal Atrophy Drugs Market Restraints

10 Global Market Forecast
10.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Type (2022-2027)
10.2 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Application (2022-2027)
10.3 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Postmenopausal Vaginal Atrophy Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Postmenopausal Vaginal Atrophy Drugs by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Covered in This Study
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Postmenopausal Vaginal Atrophy Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Postmenopausal Vaginal Atrophy Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2016-2021) & (K Units)
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 19. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 23. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Type (2016-2021)
Table 39. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Postmenopausal Vaginal Atrophy Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2016-2021)
Table 42. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Type (2016-2021)
Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units) by Application (2016-2021)
Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Postmenopausal Vaginal Atrophy Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Application (2016-2021)
Table 47. Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit) by Application (2016-2021)
Table 48. Actavis plc Corporation Information
Table 49. Actavis plc Description and Business Overview
Table 50. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product
Table 52. Actavis plc Recent Developments/Updates
Table 53. Bionovo, Inc. Corporation Information
Table 54. Bionovo, Inc. Description and Business Overview
Table 55. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 57. Bionovo, Inc. Recent Developments/Updates
Table 58. Endoceutics, Inc. Corporation Information
Table 59. Endoceutics, Inc. Description and Business Overview
Table 60. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 62. Endoceutics, Inc. Recent Developments/Updates
Table 63. Novo Nordisk A/S Corporation Information
Table 64. Novo Nordisk A/S Description and Business Overview
Table 65. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product
Table 67. Novo Nordisk A/S Recent Developments/Updates
Table 68. Pfizer Inc. Corporation Information
Table 69. Pfizer Inc. Description and Business Overview
Table 70. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 72. Pfizer Inc. Recent Developments/Updates
Table 73. Teva Pharmaceuticals Ltd. Corporation Information
Table 74. Teva Pharmaceuticals Ltd. Description and Business Overview
Table 75. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table 77. Teva Pharmaceuticals Ltd. Recent Developments/Updates
Table 78. Therapeutics MD, Inc. Corporation Information
Table 79. Therapeutics MD, Inc. Description and Business Overview
Table 80. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product
Table 82. Therapeutics MD, Inc. Recent Developments/Updates
Table 83. Shionogi & Company Corporation Information
Table 84. Shionogi & Company Description and Business Overview
Table 85. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product
Table 87. Shionogi & Company Recent Developments/Updates
Table 88. Allergan plc Corporation Information
Table 89. Allergan plc Description and Business Overview
Table 90. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Allergan plc Postmenopausal Vaginal Atrophy Drugs Product
Table 92. Allergan plc Recent Developments/Updates
Table 93. Shionogi & Co. Ltd. Corporation Information
Table 94. Shionogi & Co. Ltd. Description and Business Overview
Table 95. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product
Table 97. Shionogi & Co. Ltd. Recent Developments/Updates
Table 98. Production Base and Market Concentration Rate of Raw Material
Table 99. Key Suppliers of Raw Materials
Table 100. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 101. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 102. Postmenopausal Vaginal Atrophy Drugs Market Trends
Table 103. Postmenopausal Vaginal Atrophy Drugs Growth Drivers
Table 104. Postmenopausal Vaginal Atrophy Drugs Market Challenges
Table 105. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Table 106. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 107. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Type (2022-2027)
Table 108. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 109. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 110. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 111. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Application (2022-2027)
Table 112. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 113. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 114. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 115. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Region (2022-2027)
Table 116. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 117. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Postmenopausal Vaginal Atrophy Drugs
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2020 & 2027
Figure 3. Vaginal Gels Product Picture
Figure 4. Creams Product Picture
Figure 5. Tablets Product Picture
Figure 6. Rings Product Picture
Figure 7. Patches Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2020 & 2027
Figure 9. Offline Stores
Figure 10. Online Stores
Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Sales 2016-2027 (K Units)
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers in 2020
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Postmenopausal Vaginal Atrophy Drugs Players: Market Share by Revenue in 2020
Figure 18. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2016-2021)
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2020
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2016-2021)
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2020
Figure 23. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Vietnam Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. U.A.E Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Type (2016-2021)
Figure 48. Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Application (2016-2021)
Figure 49. Sales Market Share of Postmenopausal Vaginal Atrophy Drugs by Application in 2020
Figure 50. Revenue Share of Postmenopausal Vaginal Atrophy Drugs by Application (2016-2021)
Figure 51. Revenue Share of Postmenopausal Vaginal Atrophy Drugs by Application in 2020
Figure 52. Manufacturing Cost Structure of Postmenopausal Vaginal Atrophy Drugs
Figure 53. Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
Figure 54. Postmenopausal Vaginal Atrophy Drugs Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed